Patrick Doyle
Chief Executive Officer
17 years' broad pharmaceutical experience. Previously Chief Corporate Development Officer at Metabolex, San
Francisco; VP, Global Head of Preclinical Partnering at Roche; and Scientific Coordinator, Novo Nordisk. Has
generated significant revenue and investor returns through strategic deals/funding.
Dr Phil Boyd
Chief Financial Officer
18 years' broad financial and management experience.
Biotechnology exposure as UK Finance Director, Evotec AG and Finance Director at Cambridge Discovery Chemistry
Ltd. Prior experience in management consulting and a scientific background.
Dr Richard Jones
Chief Medical Officer
Richard is set to join Syntaxin in December 2007 as CMO, with 20 years' experience as a Physician executive with broad, international project and senior management experience in the pharmaceutical industry holding senior positions at Aspreva, Syngenta, Johnson and Johnson and Hoffman La Roche. His extensive background in drug development in both small molecules and Biologicals cuts across all therapeutic areas and all stages of the drug development process.
Dr Charles Penn
Founder and Chief Development Officer
Previously senior medical strategy head at Glaxo / Glaxo
Wellcome and R&D Director at the UK Health Protection Agency. Has a track record of achievement in pharmaceutical
discovery and development through to market.
Dr Keith Foster
Founder and Chief Scientific Officer
Over 20 years' management experience in pharmaceutical R&D, and previously led the team that developed the
proprietary technology that is the basis of Syntaxin.
Dr John Chaddock
Head of Molecular Biology
Experience at CAMR where he was instrumental in directing the activities of multi-disciplinary teams focussed
toward the development of novel therapeutics based on bacterial proteins. Has a track record of developing
candidate molecules for selection for pre-clinical studies and expertise in patent management.
Dr Nicola Thompson
Head of Cell Biology
Over 20 years experience within the pharmaceutical industry with GlaxoWellcome and GSK, holding a range of project and alliance leadership, as well as management positions. She has drug discovery experience across a broad range of therapeutic areas with particular emphasis on respiratory, inflammatory and neurological diseases.